Video Library

Andrew Lin, PharmD, reviewed practical strategies for managing cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cytopenias associated with CAR T-cell and bispecific therapies.

Donna Catamero, ANP-BC, OCN, CCRC, highlighted the rapidly evolving multiple myeloma treatment landscape, with quadruplet therapy now standard in newly diagnosed disease, earlier use of CAR-T therapy in relapse, and emerging bispecific and...

Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...

Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...

Allison Tanner, PA-C, reviewed the recognition and management of CRS, ICANS, and other evolving toxicities associated with CAR T-cell therapy and bispecific antibodies, emphasizing the need for clinician readiness as cellular therapies...

Amy Goodrich, RN, BSN, MSN, CRNP-AC, reviewed emerging treatments and the growing challenges of therapy sequencing in DLBCL, FL, and CLL, emphasizing individualized approaches guided by patient characteristics and evolving data.

Beth Sandy, MSN, CRNP, FAPO, reviewed the clinical use and toxicity management of tyrosine kinase inhibitors across solid tumors at the 2025 Oncology Learning Network APP Institute.

Kevin Chen, PharmD, discussed the increase in recent biomarker-driven drug approvals for solid tumors at the 2025 JADPRO Annual Conference, highlighting their targeted efficacy, unique toxicity profiles, and the need for clinicians to stay up...

At the 2025 JADPRO meeting, Shila Pandey, DNP, shared insights into the development of an advanced-practice-provider-led quality assurance committee designed to improve patient safety and care quality.

Danielle Roman, PharmD, highlighted evolving treatment strategies for hormone receptor–positive, HER2-positive metastatic breast cancer, emphasizing the integration of HER2-targeted therapies, endocrine therapy, and emerging CDK4/6 inhibitors...